Processa Pharmaceuticals, Inc. (PCSA)
Automate Your Wheel Strategy on PCSA
With Tiblio's Option Bot, you can configure your own wheel strategy including PCSA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PCSA
- Rev/Share 800.8979
- Book/Share 392.2672
- PB 0.0007
- Debt/Equity 0.0042
- CurrentRatio 3.4483
- ROIC -2.1247
- MktCap 15492195.0
- FreeCF/Share -697.1434
- PFCF -1.4273
- PE -0.0003
- Debt/Assets 0.0031
- DivYield 0
- ROE -3.4235
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 5
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
Published: November 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative treatments for rare diseases, today announced that its abstract, “Adaptive Phase 2/3 Study for PCS499 (499) in Patients with Focal Segmental Glomerulosclerosis (FSGS)”, has been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2025, taking place November 5–9, 2025, in Houston, Texas.
Read More
Processa Pharmaceuticals Provides Portfolio and Business Update
Published: July 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852 Continue enrolling patients in Phase 2 study of PCS6422 Strengthened balance sheet with $7M capital infusion VERO BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, provides updates on its product pipeline, upcoming milestones and business activities.
Read More
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering
Published: June 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (the “Company”), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced the pricing of a public offering of 28,000,000 shares of common stock (or pre-funded warrants in lieu thereof), together with common warrants to purchase up to 28,000,000 shares of common stock at a combined public offering price of $0.25 per share (or pre-funded warrant in lieu thereof) and associated common warrant. The common warrants will have an exercise price of $0.25 per share, are exercisable upon issuance and will expire five years thereafter. …
Read More
About Processa Pharmaceuticals, Inc. (PCSA)
- IPO Date 2014-03-07
- Website https://www.processapharmaceuticals.com
- Industry Biotechnology
- CEO George K. Ng
- Employees 10